A confluence of events has reshaped the accessibility, evidence basis, and actionability profile for PCSK9 inhibitors. As an atherosclerosis specialist, how have these developments changed the equation and shaped your approach to CV risk reduction?

A confluence of events has reshaped the accessibility, evidence basis, and actionability profile for PCSK9 inhibitors. As an atherosclerosis specialist, how have these developments changed the equation and shaped your approach to CV risk reduction?

CLICK HERE FOR CME CREDIT

A confluence of events has reshaped the accessibility, evidence basis, and actionability profile for PCSK9 inhibitors. As an atherosclerosis specialist, how have these developments changed the equation and shaped your approach to CV risk reduction?

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Lipidologist and Atherosclerosis Specialist's Perspective

Presenter

Christie M. Ballantyne, MD

Christie M. Ballantyne, MD

Director, Center for Cardiovascular Disease Prevention

Director, Center for Cardiovascular Disease Prevention
Methodist DeBakey Heart Center
Chief of the Section of Cardiovascular Research
Baylor College of Medicine
Director of Atherosclerosis Laboratory
Professor of Medicine
Baylor College of Medicine